



ASX ANNOUNCEMENT

8 December 2015

Rodman & Renshaw Initiates Cynata Research Coverage

Cynata Therapeutics Ltd (ASX: CYP) announced today that Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC, a leading US-based investment bank, has initiated equity analyst coverage with the release of a new report on Cynata.

The full Rodman & Renshaw report can be viewed on Cynata's website at www.cynata.com.

CONTACTS:

Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com

Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email stewart.washer@cynata.com

Kirin Smith, Chief Operations Officer, US Investor Contact, +1 646-863-6519, ksmith@pcgadvisory.com

Sean Leous, Chief Communications Officer, US Media Contact, +1 646-863-8998, sleous@pcgadvisory.com

Emma Power, Monsoon Communications, Australia Media Contact, 0419 149 525, emmap@monsoon.com.au

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.